Liraglutide
CAS No. 204656-20-2
Liraglutide( Liraglutide | NNC 90-1170 | NN2211 | Saxenda, Victoza )
Catalog No. M18218 CAS No. 204656-20-2
Liraglutide is a long-acting GLP-1 receptor agonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 447 | In Stock |
|
| 10MG | 527 | In Stock |
|
| 25MG | 843 | In Stock |
|
| 50MG | 1143 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLiraglutide
-
NoteResearch use only, not for human use.
-
Brief DescriptionLiraglutide is a long-acting GLP-1 receptor agonist.
-
DescriptionLiraglutide is an analog of Glucagon-like Peptide 1 (GLP-1) and an agonist of the Glucagon-like Peptide 1 receptor that is used as a hypoglycemic agent and supplemental therapy in the treatment of Diabetes by patients who do not respond to Metformin.(In Vitro):Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drug for the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells.
-
In VitroLiraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drugfor the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells.
-
In Vivo——
-
SynonymsLiraglutide | NNC 90-1170 | NN2211 | Saxenda, Victoza
-
PathwayProteasome/Ubiquitin
-
TargetCysteine Protease
-
RecptorGLP-1
-
Research AreaEndocrinology
-
Indication——
Chemical Information
-
CAS Number204656-20-2
-
Formula Weight3751.25
-
Molecular FormulaC172H265N43O51
-
Purity>98% (HPLC)
-
SolubilityH2O : 5 mg/mL 1.33 mM
-
SMILESCCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)O)CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)O)CCCNC(=N)N)CCCNC(=N)N)C(C)C)CC(C)C)Cc1c[nH]c2c1cccc2)C)[C@@H](CC)C)Cc1ccccc1)CCC(=O)O)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1[nH]cnc1)N)C)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CO)CO)Cc1ccc(cc1)O)CC(C)C)CCC(=O)O)CCC(=O)N)C)C
-
Chemical NameGlycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bode B, et al. Am J Manag Care. 2011 Mar;17(2 Suppl):S59-70.
molnova catalog
related products
-
MK-0674
MK-0674 is an orally available, selective and potent cathepsin K inhibitor (IC50: 0.4 nM) that inhibits Cat B, Cat F, Cat L, and Cat S. It can be used in metabolism-related diseases.
-
PMSF
PMSF (Phenylmethanesulfonyl fluoride) is an irreversible inhibitor of serine proteinases.
-
SID 26681509
SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).
Cart
sales@molnova.com